Ferdinando De Vita
- Oncology top 0.5%
- Colorectal Cancer Treatments and Studies 55
- Cancer Treatment and Pharmacology 26
- HER2/EGFR in Cancer Research 25
- Pancreatic and Hepatic Oncology Research 24
- Cancer Research top 2%
-
- Gastric Cancer Management and Outcomes 66
- Metastasis and carcinoma case studies 17
- Gastroenterology top 1%
- Gastrointestinal Tumor Research and Treatment 19
- Hepatology top 5%
-
- Esophageal Cancer Research and Treatment 18
- Co-authors
- Michele OrdituraFortunato CiardielloGennaro GaliziaEva LietoGiuseppe CatalanoPaolo CastellanoCiro RomanoTeresa Troiani
- Partner nations
- ItalyUnited KingdomUnited States
In The Last Decade
Ferdinando De Vita
199 papers receiving 5.8k citations
Peers
Comparison fields: 5 of 124
- Oncology 3.4k
- Cancer Research 1.0k
- Pulmonary and Respiratory Medicine 2.2k
- Gastroenterology 350
- Hepatology 266
Countries citing papers authored by Ferdinando De Vita
This map shows the geographic impact of Ferdinando De Vita's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ferdinando De Vita with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ferdinando De Vita more than expected).
Fields of papers citing papers by Ferdinando De Vita
This network shows the impact of papers produced by Ferdinando De Vita. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ferdinando De Vita. The network helps show where Ferdinando De Vita may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ferdinando De Vita, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2024 | 3 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 0 | |
| 5 | 2023 | 6 | |
| 6 | 2022 | 33 | |
| 7 | 2022 | 8 | |
| 8 | 2021 | 6 | |
| 9 | 2021 | 6 | |
| 10 | 2020 | 3 | |
| 11 | 2019 | 30 | |
| 12 | 2017 | 1 | |
| 13 | 2013 | 109 | |
| 14 | 2009 | 17 | |
| 15 | 2008 | 23 | |
| 16 | Structure-activity relationship, physicochemical and pharmacokinetic properties of AZD2171: A highly potent inhibitor of VEGF receptor tyrosine kinases | 2004 | 9 |
| 17 | Antitumor activity of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to EGF receptor-targeted drugs. | 2003 | 6 |
| 18 | 2002 | 68 | |
| 19 | 2001 | 76 | |
| 20 | 2000 | 104 |
About Ferdinando De Vita
Ferdinando De Vita is a scholar working on Oncology, Gastroenterology and Pulmonary and Respiratory Medicine, having authored 207 papers that have together received 6.0k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (66 papers), Colorectal Cancer Treatments and Studies (55 papers), Cancer Treatment and Pharmacology (26 papers), HER2/EGFR in Cancer Research (25 papers), Pancreatic and Hepatic Oncology Research (24 papers), Gastrointestinal Tumor Research and Treatment (19 papers), Esophageal Cancer Research and Treatment (18 papers) and Metastasis and carcinoma case studies (17 papers). The work is most often cited by research in Oncology (3.4k citations), Cancer Research (1.0k citations) and Pulmonary and Respiratory Medicine (2.2k citations). Ferdinando De Vita has collaborated with scholars based in Italy, United Kingdom and United States. Frequent co-authors include Michele Orditura, Fortunato Ciardiello, Gennaro Galizia, Eva Lieto, Giuseppe Catalano, Paolo Castellano, Ciro Romano, Teresa Troiani, Francesca Ferraraccio and Anna Zamboli. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancers, Oncology Reports and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.